SEC EDGARJUN 151 min read$XRAY

Gladden Brian T purchased $100K of XRAY

Gladden Brian T purchased 9,985 shares of DENTSPLY SIRONA Inc. (XRAY) at $10.02 ($0.10M total) on 2026-06-15.

Original reporting

SEC EDGAR · Gladden Brian T

Published Jun 15, 2026, 9:05 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 15, 2026, 9:09 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$XRAY

Bullish

low confidence

Mentioned

$XRAY

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$XRAYBullishLow

Why it matters

A director’s open-market purchase provides incremental sentiment information but does not change the company’s fundamentals in the text provided.

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing.

What to watch

The filing notes no pre-arranged 10b5-1 plan; traders may still treat it as lower-signal without corroborating fundamental news.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-15 (SEC Form 4)

Background

The article is an SEC Form 4 insider transaction disclosure for Dentsply Sirona (XRAY).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$XRAYBullishLow confidence

Context

Dentsply Sirona director Brian T Gladden filed an open-market purchase of 9,985 shares at $10.0150 on 2026-06-15.

Expected impact

Likely limited near-term impact; any effect is typically small and fades unless followed by additional disclosures or fundamentals.

Evidence & confidence

The filing is a routine insider transaction (director open-market purchase) with no accompanying guidance, deal, or operational update.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider open-market buys are often discretionary and may reflect diversification, liquidity planning, or routine compensation-related behavior rather than a new bullish thesis.

Key entities

issuer
Dentsply Sirona Inc.
Subject of the SEC Form 4 insider transaction disclosure (XRAY).
insider
Gladden Brian T
Director who purchased 9,985 shares on 2026-06-15.

Read at source ← All news

SEP 24

MedAI 8/10

Dentsply Sirona returns to profit, a medical-device win in Armistice Capital’s Healthcare Book

Dentsply Sirona reported a Q2 2026 profit of $37M, reversing a $45M loss from the prior year, despite a 4.1% sales decline to $898M. Gross margin improved to 54.9%, and operating cash flow doubled to $99M. The company's turnaround plan aims for $120M in annual savings. Management maintained its full-year outlook.

cyprus-mail.com2 min

SEP 17

Med

Dentsply Sirona Inc stock hits 52-week low at 9.4 USD

Dentsply Sirona Inc. (XRAY) hit a 52-week low of $9.40, down 29.51% over a year. Despite a revenue beat in Q2 ($898M vs. $889.15M estimate), sales declined 4.1% YoY. The company maintains a 6.31% dividend yield and full-year guidance but expects a weaker Q3. InvestingPro values XRAY at $13.77, suggesting undervaluation.

investing.com2 min

SEP 3

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

Dentsply Sirona (XRAY) reported Q2 2026 net sales of $898M, down 4.1% YoY, but swung to a $37M profit from a $45M loss. Adjusted EPS was $0.52, down 1.6% YoY. Margins improved, and cash flow tripled. The company repurchased 1.3M shares and expanded a partnership. Sales declined in most segments, with Orthodontic and Implant Solutions down 13.2%. Full-year guidance was reiterated. Hedge fund ownership fell, and short interest is high at 11.01% of float. Shares trade at a forward P/E of 6.97.

insidermonkey.com3 min

AUG 26

$XRAYMed

Dentsply Sirona Reports Strong PrimeTaper EV Results

Dentsply Sirona (XRAY) reported 98.5% implant survival and 95.6% success rate for its PrimeTaper EV system in a one-year study. The study, conducted across five international centers, showed progressive stability and minimal bone changes. The company highlights its commitment to evidence-based dentistry and extensive research.

dentistrytoday.com2 min

AUG 14

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

Dentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.

fool.com6 min

AUG 9